Ten studies [7, 8, 19–21, 24, 26, 30, 31] including 35,186 patients evaluated heart failure (SGLT2 inhibitors, 18,701 patients, 356 events; placebo, 16,485 patients, 459 events). This evidence concerns the gene SLC5A2 and heart failure.